

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/853,895 10/656140
		Filing Date	May 14, 2001
		First Named Inventor	Yuanxiang TAO et al.
		Group Art Unit	1614
		Examiner Name	TBA
Sheet 1 of 1	Attorney Docket Number	001107.00130	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US			
		US			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
KKH		CA 2,273,622	12/02/00	TYMIANSKI		
		WO 97/33173	09/12/97	UNIV. OF CAL.		
		WO 97/46877	12/11/97	UNIV. OF EDINBURGH		
		WO 99/37768	07/29/99	JOHNS HOPKINS		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KKH		Woolf C.J., et al., <u>Pain</u> , "The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states", 44, pp. 293-299 (1991)	
		Ishizaki, K. et al., <u>Can. J. Anesth.</u> , "Intrathecal administered NMDA receptor antagonists reduce the MAC of isoflurane in rats", 43:7, pp. 724-730 (1996)	
		Sattler, R., et al., <u>Science</u> , "Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein", 284, pp. 1845-1848 (1999)	
		Brennan, J.E., et al., <u>The Journal of Neuroscience</u> , "Cloning and characterization of postsynaptic Density 93, a nitric oxide synthase interacting protein", 16(23), pp. 7407-7415 (1996)	
Dup., w/error		Tao, Y.-X., et al., <u>Neuroscience</u> , "Expression of PSD-95/SAP90 is critical for N-methyl-D-aspartate receptor-mediated thermal hyperalgesia in the spinal cord", 98:2, pp. 201-306 (2000)	
		Tao, F. et al., <u>Neuroreport</u> , "Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats", 12:15, pp. 3251-3255 (2001)	
		Tao, Y.-X., et al., <u>Anesthesiology</u> , "Effect of the deficiency of spinal PSD95/SAP90 on the minimum alveolar anesthetic concentration of isoflurane in rats", 94:6, pp. 1010-1015 (2001)	

Examiner Signature	Kevin K. Hill	Date Considered	September 8, 2006
-----------------------	---------------	--------------------	-------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/853,895 <i>10/656 140</i></td> </tr> <tr> <td>Filing Date</td> <td>May 14, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Roger JOHNS et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>TBA</td> </tr> <tr> <td>Attorney Docket Number</td> <td>001107.00130</td> </tr> </table>		Application Number	09/853,895 <i>10/656 140</i>	Filing Date	May 14, 2001	First Named Inventor	Roger JOHNS et al.	Group Art Unit	1614	Examiner Name	TBA	Attorney Docket Number	001107.00130
Application Number	09/853,895 <i>10/656 140</i>														
Filing Date	May 14, 2001														
First Named Inventor	Roger JOHNS et al.														
Group Art Unit	1614														
Examiner Name	TBA														
Attorney Docket Number	001107.00130														
Sheet	1	of	1												

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KKH		Chih-Ling Choi and Scheherazade Sadegh-Nassen, "HLA-DM Recognizes the Flexible Conformation of Major Histocompatibility Complex Class II", The Rockefeller University Press, J. Exp. Med., Vol. 192, No. 12, 2000, pp. 1697-1706.	
↓		L. N. Maganas and J. S. Trimmer, "Subunit Composition Determines Kv1 Potassium Channel Surface Expression", The Journal of Biological Chemistry, Vol. 275, No. 38, 2000, pp. 29685-29693.	
		Rita Sattler, Zhigang Xiong, Wei-Yang Lu, Mathias Hafner, John F. MacDonald and Michale Tymianski, "Specific Coupling of NMDA Receptor Activation to Nitric Oxide Neurotoxicity by PSD-95 Protein", Science Vol. 284, 1999, pp. 1845 - 1848.	
		Y.-X. Tao, Y.-Z. Huang, L. Mei and R. A. Johns, "Expression of PSD-95/SAP90 is Critical for N-METHYL-D-ASPARTATE Receptor-Mediated Thermal Hyperalgesia in the Spinal Cord", Neuroscience, Vol. 98, No. 2, 2000, pp. 201-206.	
Dup., w/error		Yuan-Xiong Tao, Ph.D., M.D., and Roger A. Johns, M.D., "Effect to the Efficiency of Spinal PSD-95/SAP90 on the Minimum Alveolar Anesthetic Concentration of Halothane in Rats", Anesthesiology, Vol. 94, No. 6, 2001, pp. 1-6.	
KKH		M. Migaud, P. Charlesworth, M. Dempster, L. Webster, A. Watabe, M. Makhinson, Y. He, M. Ramey, R. Morris, J. Morrison, T. O'Dell and S. Grant, "Enhanced Long-Term Potentiation and Impaired Learning in Mice with Mutant Postsynaptic Density-95 Protein", Nature, Vol. 396, 1998, pp. 433-439.	

Examiner Signature	Kevin K. Hill	Date Considered	September 8, 2006
--------------------	---------------	-----------------	-------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.